Toronto, Ontario–(Newsfile Corp. – March 17, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission’s (CQC) formal approval to begin treatments for addiction and mental health.


Previous articleGreen Market Report – Are Psychedelics Leaving Minorities Behind?
Next articleHow Can We Apply Harm Reduction to HPPD?